Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Aslan Pharmaceuticals's Eblasakimab?
Eblasakimab is a monoclonal antibody commercialized by Aslan Pharmaceuticals, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema)....
Risk adjusted net present value: What is the current valuation of Aslan Pharmaceuticals's Eblasakimab?
Eblasakimab is a monoclonal antibody commercialized by Aslan Pharmaceuticals, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema)....
Eblasakimab by Aslan Pharmaceuticals for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Eblasakimab is under clinical development by Aslan Pharmaceuticals and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to...